Repository logo
 

Structure of the Toll/Interleukin-1 Receptor (TIR) Domain of the B-cell Adaptor That Links Phosphoinositide Metabolism with the Negative Regulation of the Toll-like Receptor (TLR) Signalosome

Published version
Peer-reviewed

Change log

Authors

Halabi, S 
Sekine, E 
Verstak, B 
Gay, NJ 
Moncrieffe, MC 

Abstract

Ligand binding to Toll-like receptors (TLRs) results in dimerization of their cytosolic Toll/interleukin-1 receptor (TIR) domains and recruitment of post-receptor signal transducers into a complex signalosome. TLR activation leads to the production of transcription factors and pro-inflammatory molecules and the activation of phosphoinositide 3-kinases (PI3K) in a process that requires the multimodular B-cell adaptor for phosphoinositide 3-kinase (BCAP). BCAP has a sequence previously proposed as a "cryptic" TIR domain. Here, we present the structure of the N-terminal region of human BCAP and show that it possesses a canonical TIR fold. Dimeric BCAP associates with the TIR domains of TLR2/4 and MAL/TIRAP, suggesting that it is recruited to the TLR signalosome by multitypic TIR-TIR interactions. BCAP also interacts with the p85 subunit of PI3K and phospholipase Cγ, enzymes that deplete plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2), and these interactions provide a molecular explanation for BCAP-mediated down-regulation of inflammatory signaling.

Description

Keywords

BCAP, BCAP adaptor, MAL/TIRAP, PI3 kinase, PLCγ2, TIR domain, Toll-like receptor, Toll-like receptor (TLR), crystal structure, pathway crosstalk, phosphatidylinositide 3-kinase (PI 3-kinase), phosphatidylinositol 4,5-bisphosphate, phospholipase C

Journal Title

Journal of Biological Chemistry

Conference Name

Journal ISSN

0021-9258
1083-351X

Volume Title

292

Publisher

American Society for Biochemistry and Molecular Biology Inc.
Sponsorship
Medical Research Council (G1000133)
Wellcome Trust (100321/Z/12/Z)
This work was supported by a program grant from the UK Medical Research Council (G1000133) and a Wellcome Investigator award (WT100321/z/12/Z to N. J. G.).